Camurus’ NDA Resubmission for CAM2029 in Acromegaly Accepted for Review by the US FDA

Дата публикации: 17-07-2026 02:07:59

Lund, Sweden — 17 July 2026 — Camurus (NASDAQ STO: CAMX) today announced that the US Food and Drug Administration (FDA) has accepted for review the resubmission of the New Drug Application (NDA) for CAM2029, octreotide...

Схожие новости

#	Наименование новости	Тональность	Информативность	Дата публикации
1	Camurus Provides Regulatory Update on the US NDA for CAM2029 (Oclaiz™) in Acromegaly	0	13.28	10-06-2026
2	Cemdisiran Regulatory Submissions Accepted for Review by FDA and EMA for the Treatment of Generalized Myasthenia Gravis (gMG)	0	9.64	22-06-2026
3	Saol Therapeutics Announces the Acceptance of Resubmission of SL1009 (DCA) by the FDA with PDUFA Date of Dec. 30, 2026	0	15.84	28-07-2026
4	Ascelia Pharma Provides Update on the Orviglance NDA	0	11.3	03-07-2026
5	Capricor Therapeutics Provides Update on FDA Advisory Committee Meeting for Deramiocel	0	13.9	30-07-2026
6	Apnimed Announces FDA Acceptance of New Drug Application for AD109, An Investigational Oral Pill to Treat Adults with Obstructive Sleep Apnea	0	14.56	14-07-2026
7	Axsome Therapeutics Announces FDA Acceptance of New Drug Application for AXS-12 for the Treatment of Cataplexy in Narcolepsy	0	8.61	15-07-2026
8	New Drug Application for Bayer’s FXIa Inhibitor Asundexian Accepted by U.S. Food and Drug Administration Under Priority Review	0	7.56	19-05-2026
9	Lundbeck Receives FDA Fast Track Designation for Lu AH69593, an Investigational Orexin 2 Receptor Agonist for Narcolepsy	0	13.22	23-07-2026
10	Scholar Rock Announces FDA Review of Apitegromab Biologics License Application (BLA) for Spinal Muscular Atrophy (SMA) to Progress with Second Fill-Finish Facility	0	13.33	07-08-2026

Классификация: Пресс-релизы. Схожих патентов: 0. Схожих новостей: 10. Тональность: 0. Информативность: 10.06. Источник: www.drugs.com.